Skip to content

Clinical Evaluation Of The PARADYM RF Device

Clinical Evaluation Of The PARADYM RF Device SORIN GROUP'S New IDC Platform

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01193634
Enrollment
75
Registered
2010-09-02
Start date
2010-10-31
Completion date
2012-03-31
Last updated
2014-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

ICD VR 9250, DR 9550 and CRT 9750 - PARADYM RF ICD

Brief summary

The PARADYM RF ICDs (DR, VR and CRT)have been implemented with 3 innovative features: The new RV autothreshold algorithm which will help the physician in his diagnosis avoiding potential lost of capture. Then, the ICD devices have also the capability to be remotely interrogated through the remote monitoring system whose performances will be reported during the study. Finally the study will report the electrical and handling performances of the new left ventricular lead.

Detailed description

In the PARADYM RF clinical study, the sponsor aims at: * Demonstrating the performances of the right ventricular autothreshold algorithm ; * Reporting the adverse events documented in the study; * Reporting electrical performances of Sorin Group PARADYM ICDs, in order to validate that the performances of those devices are in conformance with longevity and effectiveness objectives; * Assessing the user satisfaction (patient and physician) of the remote monitoring solution and the overall availability of the system in terms of data. * Reporting the Situs 2 MV left ventricular lead performances; * Reporting the Situs 2 MV LV lead mechanical handling. Thus, this study intends to show that PARADYM RF ICDs operate safely and appropriately in intended-use as part of an ICD system.

Interventions

DEVICEVR 9250 / DR 9550 / CRT 9750

Active implantable defibrillators range

Sponsors

LivaNova
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* In case of implantation of VR 9250: patient has been prescribed the implantation or replacement of a single-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of single-chamber ICD; * In case of implantation of DR 9550: patient has been prescribed the implantation or replacement of a dual-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of dual-chamber ICD; * In case of implantation of CRT 9750: patient has been prescribed the implantation or replacement of a triple-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC3 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of triple-chamber ICD;

Exclusion criteria

* 1 VT/VF is associated with drug toxicity, electrolyte imbalance, hypoxia, or other reversible cause; * 2 VT/VF occurred during the acute phase of infarction (\< 3 weeks) or during an unstable ischemic phase; * 3 VF was caused by electrocution; * 4 Incessant VT/VF ; * 5 Implanted pacemaker that is not going to be explanted or otherwise disabled; * 6 Patient is unable to attend the scheduled follow-ups at the implanting centre; * 7 Patient is already enrolled in another ongoing clinical study; * 8 Patient is unable to understand the aim of the study and its procedure; * 9 Patient refuses to cooperate; * 10 Patient is unable or refuses to provide informed consent; * 11 Patient is minor (less than 18-year old); * 12 Patient is pregnant; * 13 Patient has life expectancy of less than 1 year; * 14 Patient is forfeiture of freedom or under guardianship.

Design outcomes

Primary

MeasureTime frameDescription
Demonstration of the Right ventricular (RV) autothreshold algorithm performances1 monthDemonstrate that the automatic RV pacing thresholds measures are equivalent to the manual test.

Secondary

MeasureTime frameDescription
Incidence of adverse events12 monthsAny adverse event will be documented throughout the study and will be reported.
ICD electrical performances12 monthsReport all ICD electrical performances of the Paradym RF ICD.
Evaluation of the left ventricular lead performances12 monthsReport the electrical performances and lead mechanical handling at implant.
Evlauation of the Remote Monitoring Solution12 monthsEnsure the Home Monitoring setup procedure and daily life use are user friendly for the patient and the back office is convenient for the physician.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026